The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is helping patients live longer with acute myeloid leukaemia (AML).
Adjuvant treatment with the chemotherapy doublet of pemetrexed and cisplatin did not lead to a significant improvement in overall survival compared with vinorelbine plus cisplatin in patients with stage II to IIIA nonsquamous non–small cell lung cancer.
Trastuzumab plus ramucirumab and paclitaxel yielded promising efficacy and a manageable safety profile among patients with previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
The study results of the ALL-11 treatment protocol, led by researchers at the Princess Maxima Center, were published in the scientific Journal of Clinical Oncology.